TPP: What IP Professionals Need to Know

MBHB Partner Dr. Kevin Noonan is a featured co-presenter at this Innography-sponsored webinar set for 11:00 a.m. CDT on October 21, 2015.

Overview

Trade partners negotiating the Trans-Pacific Partnership (TPP) trade deal have reached an agreement that will have implications for intellectual property professionals, including significant negative consequences for the biopharma industry. Presently, the United States provides 12 years of data exclusivity for advanced medicines made from living organisms. The TPP agreement knocks that term down to 5 years. While the term of data exclusivity is not one in the same with reducing the term of market exclusivity, limited data exclusivity would likely lead to significant negative consequences for the biopharma industry.

About This Webinar

• The difference between data exclusivity and market exclusivity.
  
• How decreased data exclusivity will impact the biopharma industry.
  
• The significant and costly regulatory hurdles necessary to collect the required data to satisfy FDA requirements.
  
• The likelihood that Congress will ratify the TPP agreement without modification of the data exclusivity term.

Sponsored by Innography.